Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.

By T. Inagaki, Paul A. Dutchak, Guixiang Zhao, Xunshan Ding, L. Gautron, Vinay K. Parameswara, Yong Li, R. Goetz, M. Mohammadi, V. Esser and 6 more. Cell Metabolism, 2007

1,532 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/83f56cdf83caeaf7963918958a0aa613e2aaa684

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Gerald I. Shulman
2. V. Samuel
3. B. Spiegelman
4. A. Beenken
5. Liangyou Rui
6. M. Mohammadi
7. N. Itoh
8. Jun Wu

In Physiology

1. V. Samuel
2. Gerald I. Shulman
3. B. Spiegelman
4. Jun Wu
5. P. Cohen
6. B. Desvergne
7. D. Moller
8. P. Crawford

Citations in the corpus

• Non-Alcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases (2017, positive): “FGF21 coordinates the metabolic shift from fed to fasted states; FGF21 regulates hepatic ketogenesis, gluconeogenesis, and adipose lipolysis (Badman et al., 2007; Inagaki et al., 2007).”
• Homeostasis, Inflammation, and Disease Susceptibility (2015, neutral): “FGF21 is produced by hepatocytes during fasting (Badman et al., 2007; Inagaki et al., 2007) and potentially reports on flow of fatty acids from the adipocytes during lipolysis.”
• Adaptive thermogenesis in adipocytes: is beige the new brown? (2013, background): “FGF21 is an endocrine hormone that belongs to the FGF family and has been shown to play an important role in regulating the fasting response in the liver (Kharitonenkov et al. 2005; Badman et al. 2007; Inagaki et al. 2007).”
• FGF/FGFR signaling in health and disease (2020, background): “FGF21 in WAT is induced by fasting/refeeding regimens and the thiazolidinedione drugs.(558) FGF21 in BAT is induced by cold exposure.”
• Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota (2017, positive): “, 2012; Harms and Seale, 2013) and the adaptive fasting response (Inagaki et al., 2007).”
• Endocrine disruptors: from endocrine to metabolic disruption. (2011, background): “These effects were not observed in PPARα-null mice, confirming that in vivo DEHP activity is mediated primarily by PPARα in the liver, leading to increased fatty acid catabolism and induced expression of PPARα target genes such as that encoding fibroblast growth factor 21 (FGF21) (137) or genes cont”
• Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice (2009, background): “Furthermore, transgenic mice with hepatic overexpression of FGF21 were lean and protected from high-fat diet–induced insulin resistance (5,9).”
• Fibroblast growth factor 21 corrects obesity in mice. (2008, background): “As expected based on previously reported results (2, 4, 5, 7), insulin levels were suppressed, and this effect reached its maximum at the lowest dose of FGF21.”
• Energy Metabolism in the Liver (2014, positive): “FGF21 is largely produced and secreted by hepatocytes (9, 91).”